Latest
marketscreener.com Market update
News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 1–20
- Matches
- 20
- Sources here
- 9
- Companies here
- 1
Search results
Stored financial headlines
Active search
20 matching headlines
Ticker or company: XRTXMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
XORTX Therapeutics Inc. Announces Resignation of Anthony Giovinazzo from Director Role
XORTX Therapeutics Inc. announced the resignation of Anthony Giovinazzo from its board of directors. Giovinazzo served as chairman of the board for several years and is stepping down for personal reasons and to pursue other interests. The company acknowledged his significant contributions and leadership …
XRTX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -48.7% · Next-week setup negative 43.4%
XORTX Director Anthony Giovinazzo Steps Down for Personal Reasons
XORTX Therapeutics Inc. announced that Anthony Giovinazzo has resigned from its board of directors for personal reasons and to pursue other interests. Co-CEO Dr. Allen Davidoff expressed gratitude for Giovinazzo's leadership and ethics during his tenure as chairman. XORTX remains focused on developing therapies …
XRTX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -48.7% · Next-week setup negative 43.4%
XORTX Therapeutics Adds Independent Director to Strengthen Board Oversight
XORTX Therapeutics Inc. has appointed Depesh Narotam as an independent director to its board, aiming to enhance governance and financial oversight. Narotam brings over two decades of experience in debt financing and strategic lending and will also serve on the Compensation, Governance and Nominating …
XRTX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -48.7% · Next-week setup negative 43.4%
XORTX Therapeutics (NASDAQ: XRTX) appoints Depesh Narotam as independent director
XORTX Therapeutics, a late-stage clinical pharmaceutical company, has appointed Depesh Narotam as an independent director to its board, effective July 27, 2026. Narotam, with over 20 years of financial services experience, will also serve on the Compensation, Governance and Nominating Committee. This appointment is …
XRTX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -48.7% · Next-week setup negative 43.4%
XORTX Board Gains Director With Over 20 Years in Financial Services
XORTX Therapeutics (NASDAQ: XRTX) has appointed Depesh Narotam as an independent director to its board, effective July 27, 2026. Mr. Narotam brings over 20 years of financial services experience, specializing in debt financing and strategic lending, and will serve on the Compensation, Governance and …
XRTX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -48.7% · Next-week setup negative 43.4%
XORTX Appoints New Director
XORTX Therapeutics Inc. has announced the appointment of Depesh Narotam to its board of directors as an independent director, effective July 27, 2026. Mr. Narotam brings over 20 years of experience in the financial services industry, specializing in debt financing and strategic lending solutions. …
XRTX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -48.7% · Next-week setup negative 43.4%
XORTX Therapeutics Inc (XRTX) Institutional Confidence
The article provides an overview of XORTX Therapeutics Inc (XRTX), focusing on its institutional confidence through shareholder activity. It lists significant institutional and individual shareholders and their respective shareholdings and changes. Key details include the company's current stock price, market capitalization, and links to …
XRTX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -48.7% · Next-week setup negative 43.4%
XRTX|XORTX Therapeutics Inc|Price:2.025|Chg%:-0.090
The article provides a comprehensive stock analysis of XORTX Therapeutics Inc (XRTX) by TradingKey, focusing on its stock score and various underlying components. Due to insufficient data, a stock score is not yet available, but the article details how TradingKey generates scores for financial …
XRTX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -48.7% · Next-week setup negative 43.4%
XORTX Therapeutics Inc (XRTX) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of XORTX Therapeutics Inc (XRTX) stock, focusing on its dividend history and stock split events. It highlights that the company has not distributed dividends in the past five years and details several stock split (merger) events, including future and …
XRTX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -48.7% · Next-week setup negative 43.4%
TradingKey
This article provides a detailed cash flow statement for XORTX Therapeutics Inc (XRTX), presenting quarterly and annual financial data. It itemizes operating, investing, and financing cash flows, along with changes in working capital and other financial metrics. The document also includes an FAQ section …
XRTX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -48.7% · Next-week setup negative 43.4%
XORTX Therapeutics Inc (XRTX) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for XORTX Therapeutics Inc (XRTX), focusing on its volatility, financial metrics, and investment risk. It details various risk-related statistics including बीटा vs S&P 500 index, Maximum Drawdown, Volatility, Sharpe Ratio, and Liquidity metrics. The data presented covers different …
XRTX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -48.7% · Next-week setup negative 43.4%
XRTX Income Statement
This article provides the quarterly and annual income statements for XORTX Therapeutics Inc (XRTX) from FY2018Q1 to FY2026Q1, detailing operating expenses, R&D expenses, depreciation, operating profit, various non-operating incomes/expenses, and net income figures. It also includes frequently asked questions about understanding and analyzing income …
XRTX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -48.7% · Next-week setup negative 43.4%
XORTX Therapeutics Inc. Revenue Breakdown – NASDAQ:XRTX
This article from TradingView is a financial page for XORTX Therapeutics Inc. (NASDAQ: XRTX), focusing on its revenue breakdown. It provides links to various financial data, including statements, statistics, dividends, earnings, and segments, though specific revenue figures are not detailed in the provided text. …
XRTX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -48.7% · Next-week setup negative 43.4%
XORTX Therapeutics Inc (XRTX) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of XORTX Therapeutics Inc (XRTX), listing major shareholders by proportion, including Lincoln Alternative Strategies LLC and DRW Securities, LLC. It also breaks down shareholder types and provides a quarterly overview of institutional shareholdings and recent shareholder activity with …
XRTX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -48.7% · Next-week setup negative 43.4%
XORTX Therapeutics (XRTX) Stock Forecast & Analyst Ratings
This article provides a stock forecast and analyst ratings for XORTX Therapeutics (XRTX). It covers various financial aspects and expert opinions regarding the company's stock performance.
XRTX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -48.7% · Next-week setup negative 43.4%
XORTX Therapeutics (XRTX) Q4 2024 earnings summary
XORTX Therapeutics (XRTX) reported an unqualified audit opinion for 2024, but with material uncertainty regarding its ability to continue as a going concern due to recurring operating losses and the need for additional financing. The company's cash decreased to $2.47M, and it reported a …
XRTX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -48.7% · Next-week setup negative 43.4%
XORTX Therapeutics (XRTX) Investor presentation Summary
This article summarizes an investor presentation by XORTX Therapeutics (XRTX), highlighting its drug candidates XRx-026 for gout and XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD). XRx-026 targets a significant market opportunity with NDA submission planned for H2 2027, addressing unmet needs in allopurinol-intolerant …
XRTX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -48.7% · Next-week setup negative 43.4%